共被期刊论文引用了2次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ribavirin and IFN-α combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B显示文摘AIM: To investigate the anti-viral mechanism of combination therapy of interferon (IFN)-α and ribavirin in patients with chronic hepatitis B. METHODS: Twenty patients were assigned to receive either IFN-α plus ribavirin (group A,n = 14) or no treatment as a control (group B,n = 6). Patients were analyzed for T-cell proliferative responses specific for hepatitis B virus (HBV)-antigen and cytokine production by peripheral blood mononuclear cells (PBMCs). RESULTS: Combination therapy induced HBV-antigen specific CD4+ T-cell proliferative responses in four patients (28.6%). Production of high levels of HBV-specific IFN-γ,tumor necrosis factor (TNF)-α,interleukin (IL)-12 by PBMCs was found in five patients (35.7%),who showed significantly lower HBV DNA levels in serum at 12 mo after treatment ended (P = 0.038) and at 24 mo of follow-up (P = 0.004) than those without high levels of cytokine production. CONCLUSION: HBV-antigen specific CD4+ T cells may directly control HBV replication and secretion of anti-viral T helper 1 (Th1) cytokines by PBMCs during combination therapy of chronic hepatitis B with ribavirin and IFN-α. | Fen-Yu Ren Hai Jin Xi-Xu Piao Feng-Shun Piao | 2007 | World Journal of Gastroenterology2007，13，41： | 4 |
| 2 | 急性白血病患者合并乙型肝炎病毒感染的研究现状显示文摘目前, 对急性白血病(AL)患者主要采取细胞毒性药物化疗、造血干细胞移植治疗为主, 免疫疗法、靶向药物的治疗手段也正在探索中。AL患者易发生乙型肝炎病毒(HBV)感染。合并HBV感染的AL患者依据其血清学状态、HBV DNA水平、疾病亚型及治疗方案的不同, 存在不同级别的HBV再激活(HBVr)风险。HBVr对AL患者的临床疗效及生存预后存在一定影响, 可导致患者的临床结局不同。目前对于AL合并HBV感染患者的研究较少, 对患者综合管理及预防性治疗方法尚无权威指南。笔者拟通过对AL患者的HBV感染率, HBVr发生率及其影响因素, 以及HBVr最佳预防药物、用药时机和疗程选择的研究现状进行阐述, 为AL合并HBV感染患者的临床管理提供参考。 | 江兆清 洪鸣 | 2022 | 国际输血及血液学杂志2022，45，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员